Dennis A. Eichenauer

6.6k total citations · 2 hit papers
128 papers, 3.3k citations indexed

About

Dennis A. Eichenauer is a scholar working on Pathology and Forensic Medicine, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Dennis A. Eichenauer has authored 128 papers receiving a total of 3.3k indexed citations (citations by other indexed papers that have themselves been cited), including 100 papers in Pathology and Forensic Medicine, 62 papers in Oncology and 39 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Dennis A. Eichenauer's work include Lymphoma Diagnosis and Treatment (100 papers), Lung Cancer Treatments and Mutations (37 papers) and Viral-associated cancers and disorders (33 papers). Dennis A. Eichenauer is often cited by papers focused on Lymphoma Diagnosis and Treatment (100 papers), Lung Cancer Treatments and Mutations (37 papers) and Viral-associated cancers and disorders (33 papers). Dennis A. Eichenauer collaborates with scholars based in Germany, United States and Switzerland. Dennis A. Eichenauer's co-authors include Andreas Engert, Peter Borchmann, Boris Böll, Martin Hutchings, Massimo Federico, Tim Illidge, Marco Ladetto, M. André, Michael Fuchs and Volker Diehl and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Dennis A. Eichenauer

115 papers receiving 3.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

COVID‐19 associated pulmonary aspergillosis

2020 401 citations Dennis A. Eichenauer, Michael Hallek et al. profile →
Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

2014 324 citations Dennis A. Eichenauer, Andreas Engert et al. Annals of Oncology profile →

Peers

Countries citing papers authored by Dennis A. Eichenauer

Since Specialization

Citations

This map shows the geographic impact of Dennis A. Eichenauer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dennis A. Eichenauer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dennis A. Eichenauer more than expected).

Fields of papers citing papers by Dennis A. Eichenauer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dennis A. Eichenauer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dennis A. Eichenauer. The network helps show where Dennis A. Eichenauer may publish in the future.

Co-authorship network of co-authors of Dennis A. Eichenauer

This figure shows the co-authorship network connecting the top 25 collaborators of Dennis A. Eichenauer. A scholar is included among the top collaborators of Dennis A. Eichenauer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dennis A. Eichenauer. Dennis A. Eichenauer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Fatal outcome of severe serotonin syndrome and acute respiratory distress syndrome after self-poisoning with paroxetine: a case report 2025 ·Journal of Medical Case Reports ·Sina M. Hopff, (unknown), Oezguer A. Onur, (unknown), Dennis A. Eichenauer, Jan‐Hendrik Naendrup, (unknown), Nathalie Schmidt, (unknown), Boris Böll	0
2	Brentuximab Vedotin, Cyclophosphamide, Doxorubicin and Prednisone (B-CAP) First-Line Treatment of Advanced-Stage Hodgkin Lymphoma: Final Results of the GHSG-NLG Phase II Bvb Trial 2024 ·Blood ·Paul J. Bröckelmann, Boris Böll, Daniël G. M. Molin, (unknown), Sirpa Leppä, Julia Meißner, Peter Kamper, Martin Hutchings, Jacob Haaber Christensen, Ulf Schnetzke, (unknown), Dennis A. Eichenauer, Bastian von Tresckow, (unknown), Peter Borchmann, Alexander Fosså	0
3	Involved-site Radiation Therapy is Equally Effective and Less Toxic Than Involved-field Radiation Therapy in Patients Receiving Combined Modality Treatment for Early-stage Unfavorable Hodgkin Lymphoma—An Analysis of the Randomized Phase 3 HD17 Trial of the German Hodgkin Study Group 2024 ·International Journal of Radiation OncologyBiologyPhysics ·Johannes Rosenbrock, (unknown), Michael Oertel, Eren Celik, (unknown), Jiaqi Fan, Dennis A. Eichenauer, Paul J. Bröckelmann, Bastian von Tresckow, Carsten Kobe, Markus Dietlein, Michael Fuchs, Peter Borchmann, Hans Theodor Eich, Christian Baues	1
4	Palliative care for patients with hematologic malignancies in Germany: a nationwide survey on everyday practice and influencing factors from the perspective of treating physicians 2024 ·Annals of Hematology ·(unknown), (unknown), (unknown), Steffen T. Simon, Dennis A. Eichenauer, Anne Pralong, Ulrich Wedding	2
5	Treatment of Nodular Lymphocyte-Predominant Hodgkin Lymphoma: Where Do We Stand? Where Do We Go? 2023 ·Cancers ·Dennis A. Eichenauer, Michael Fuchs	1
6	Hyperleukocytosis in patients with acute myeloid leukemia admitted to the intensive care unit: a single-center retrospective analysis 2023 ·Leukemia Research ·Jan‐Michel Heger, Boris Böll, Jan‐Hendrik Naendrup, Florian Simon, (unknown), Michael Hallek, Alexander Shimabukuro‐Vornhagen, Matthias Kochanek, Dennis A. Eichenauer, Jorge Garcia Borrega	4
7	Behandlung der hämophagozytischen Lymphohistiozytose bei Patienten auf der Intensivstation 2023 ·Die Innere Medizin ·Dennis A. Eichenauer, Paul La Rosée	1
8	Characteristics and outcomes of patients undergoing high-dose chemotherapy and autologous stem cell transplantation admitted to the intensive care unit: a single-center retrospective analysis 2022 ·Annals of Hematology ·Jorge Garcia Borrega, Boris Böll, Matthias Kochanek, Jan‐Hendrik Naendrup, Florian Simon, (unknown), Michael Hallek, Peter Borchmann, Udo Holtick, Alexander Shimabukuro‐Vornhagen, Dennis A. Eichenauer, Jan‐Michel Heger	2
9	Brentuximab vedotin-containing escalated BEACOPP variants for newly diagnosed advanced-stage classical Hodgkin lymphoma: follow-up analysis of a randomized phase II study from the German Hodgkin Study Group 2021 ·Leukemia ·(unknown), Helen Goergen, Stefanie Kreissl, Annette Plütschow, (unknown), Stephan Mathas, Julia Meißner, Martin Sökler, Max S. Topp, Vladan Vučinić, Andreas Zimmermann, Bastian von Tresckow, Michael Fuchs, Andreas Engert, Peter Borchmann, Dennis A. Eichenauer	18
10	PET-2-guided escalated BEACOPP for advanced nodular lymphocyte-predominant Hodgkin lymphoma: a subgroup analysis of the randomized German Hodgkin Study Group HD18 study 2021 ·Annals of Oncology ·Dennis A. Eichenauer, Stefanie Kreissl, (unknown), Christian Baues, Carsten Kobe, (unknown), Helen Goergen, Michael Fuchs, Sylvia Hartmann, Bastian von Tresckow, Andreas Engert, Peter Borchmann	13
11	Evolutionary clonal trajectories in nodular lymphocyte-predominant Hodgkin lymphoma with high risk of transformation 2021 ·Haematologica ·Lisa Paschold, Edith Willscher, (unknown), Martine Vornanen, Dennis A. Eichenauer, Donjetë Simnica, Benjamin Thiele, Claudia Wickenhauser, Andreas Rosenwald, (unknown), Wolfram Klapper, Alfred C. Feller, German Ott, Falko Fend, Sylvia Hartmann, Mascha Binder	10
12	Prognostic accuracy of SOFA, qSOFA and SIRS criteria in hematological cancer patients: a retrospective multicenter study 2019 ·Journal of Intensive Care ·(unknown), Enrico Schalk, Tobias Liebregts, (unknown), (unknown), Michael von Bergwelt‐Baildon, Nina Hesse, (unknown), Jörg Janne Vehreschild, Alexander Shimabukuro‐Vornhagen, Dennis A. Eichenauer, (unknown), Matthias Kochanek, Boris Böll	32
13	Pharmacotherapy of Hodgkin lymphoma: standard approaches and future perspectives 2014 ·Expert Opinion on Pharmacotherapy ·Dennis A. Eichenauer, Boris Böll, Volker Diehl	7
14	The prognostic impact of variant histology in nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group (GHSG) 2013 ·Blood ·Sylvia Hartmann, Dennis A. Eichenauer, Annette Plütschow, Anja Mottok, Roshanak Bob, Karoline Koch, Heinz‐Wolfram Bernd, Sergio Cogliatti, Michael Hummel, Alfred C. Feller, German Ott, Peter Mӧller, Andreas Rosenwald, Harald Stein, Martin‐Leo Hansmann, Andreas Engert, Wolfram Klapper	112
15	Brentuximab vedotin for relapsed or refractory CD30+ hematologic malignancies: the German Hodgkin Study Group experience 2012 ·Blood ·Achim Rothe, Stephanie Sasse, Helen Goergen, Dennis A. Eichenauer, Andreas Lohri, Ulrich Jäger, Christopher Bangard, Boris Böll, (unknown), Sebastian Theurich, Peter Borchmann, Andreas Engert	60
16	Fertility and gonadal function in female survivors after treatment of early unfavorable Hodgkin lymphoma (HL) within the German Hodgkin Study Group HD14 trial 2012 ·Annals of Oncology ·Karolin Behringer, Indra Thielen, Horst Mueller, Helen Goergen, (unknown), Johannes Rosenbrock, Teresa Halbsguth, Dennis A. Eichenauer, Michael Fuchs, Katrin S. Reiners, (unknown), Katrin van der Ven, (unknown), Michael von Wolff, Volker Diehl, Andreas Engert, Peter Borchmann	63
17	Advances in the treatment of Hodgkin lymphoma 2012 ·International Journal of Hematology ·Dennis A. Eichenauer, Andreas Engert	19
18	State of the art in the treatment of Hodgkin lymphoma 2012 ·Nature Reviews Clinical Oncology ·Peter Borchmann, Dennis A. Eichenauer, Andreas Engert	57
19	Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up 2010 ·Annals of Oncology ·Andreas Engert, Dennis A. Eichenauer, M. Dreyling	42
20	Hodgkin's lymphoma: ESMO Clinical Recommendations for diagnosis, treatment and follow-up 2009 ·Annals of Oncology ·Andreas Engert, Dennis A. Eichenauer, Martin Dreyling	48

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact